Highlights BetterLife Pharma Inc.

Equities

BETR.F

CA08772P2026

Market Closed - OTC Markets Other stock markets 16:53:40 17/05/2024 BST			5-day change	1st Jan Change
0.087 ^USD	-8.03%		-0.34%	+81.25%

05-14	BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001	CI
05-03	BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001	05-14	CI
BetterLife Pharma Advances IND-enabling Studies For BETR-001	05-01	MT
BetterLife Pharma Inc. Advances BETR-001 IND-Enabling Studies	05-01	CI
BetterLife Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	12-29	CI
Us Patent and Trademark Office Publishes Betterlife?S Comprehensive Patent for Betr-001 and Other Lsd Derivatives	11-30	CI
BetterLife Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	27/09/23	CI
BetterLife Pharma Inc. Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001	12/09/23	CI
BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	28/06/23	CI
BetterLife Pharma Inc. Fast Tracking Its US Patent for BETR-001 and Other LSD Derivatives	27/06/23	CI
BetterLife Pharma Inc. Continues Progress on BETR-001 IND-Enabling Studies	08/06/23	CI
BetterLife Pharma Inc. Reports Earnings Results for the Full Year Ended January 31, 2023	31/05/23	CI
BetterLife Pharma Inc. to Present BETR-001 Preclinical Data At the 2023 Annual Meeting of the Society of Biological Psychiatry in San Diego, California	25/04/23	CI
BetterLife Pharma Inc. Publishes Promising Results from Study Titled "A Non-Hallucinogenic LSD Analog with Therapeutic Potential for Mood Disorders	09/03/23	CI
BetterLife Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	22/12/22	CI
BetterLife Pharma Present BETR-001 Preclinical Data at Annual Meeting of American College of Neuropsychopharmacology	02/12/22	MT
BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology in Phoenix, Arizona	02/12/22	CI
BetterLife Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	27/09/22	CI
BetterLife Pharma Inc. Files Comprehensive Patent for BETR-001 and Other LSD Derivatives	27/09/22	CI
BetterLife Pharma Inc. Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies	06/07/22	CI
BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2022	28/06/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BetterLife Pharma Inc.

Equities

BETR.F

CA08772P2026

Highlights

Filters